Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Peschiera Del Garda – page 2

39 clinical trials in Peschiera Del Garda, Italy. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Peschiera Del Garda at a glance
39
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

39 trials in Peschiera Del Garda

Open in trial search

Non-small cell lung cancer+2

Recruiting

Study Comparing Nivolumab and Relatlimab with Chemotherapy to Pembrolizumab with Chemotherapy for Advanced Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Small cell lung cancer extensive stage

Recruiting

Study Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Gilead Sciences Inc.

Hormone-dependent prostate cancer

Recruiting

Study on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Small cell lung cancer extensive stage

Recruiting

Study Comparing BMS-986489 with Chemotherapy to Atezolizumab with Chemotherapy for First-Line Treatment in Patients with Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Squamous cell carcinoma of lung+2

Recruiting

Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:OSE Immunotherapeutics

Study Comparing FOLFIRI with Cetuximab or Bevacizumab for First-Line Treatment in Patients with Metastatic Colorectal Cancer and Specific Genetic Profiles

Recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Azienda USL IRCCS Di Reggio Emilia

Colorectal cancer metastatic

Recruiting

Study on Intermittent vs. Continuous Panitumumab and FOLFIRI for Patients with Unresectable Left-Sided Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Non-small cell lung cancer

Not yet recruiting

Study of N-803, tislelizumab and docetaxel combination versus docetaxel alone for patients with advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Immunitybio Inc.

Non-small cell lung cancer stage IV

Not yet recruiting

Osimertinib and drug combination in metastatic non‑small cell lung cancer with targetable genomic driver alterations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Universita' Degli Studi Di Torino

Non-small cell lung cancer

Not yet recruiting

Phase 2 Study of Safety and Efficacy of PF-08634404 Alone or with Drug Combination in Adults with Early-Stage or Locally Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Pfizer Inc.

Hepatocellular carcinoma

Not yet recruiting

Advanced hepatocellular carcinoma patients: assessing atezolizumab drug combination and other treatment sequences

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Peschiera Del Garda

What the registry says about research in the country

01 Lung Cancer Research

Extensive research focusing on non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), evaluating novel combination therapies and immunotherapy approaches.

  • Advanced treatment combinations
  • Immunotherapy efficacy
  • Metastatic disease management

Multiple trials investigating targeted therapies in combination with chemotherapy for improved patient outcomes.

02 Breast Cancer Studies

Innovative research examining ER+/HER2- breast cancer treatments, with particular focus on preventing distant metastasis and improving survival rates.

  • Endocrine therapy comparison
  • Metastasis prevention
  • Biomarker analysis

Studies evaluating new therapeutic approaches for early-stage breast cancer patients.

03 Colorectal Cancer Investigations

Research focusing on metastatic colorectal cancer treatment strategies, particularly in patients with specific genetic profiles.

  • Targeted therapy optimization
  • Treatment scheduling evaluation
  • Biomarker-driven approaches

Studies comparing continuous versus intermittent treatment protocols for optimal patient outcomes.

04 Specialized Cancer Therapies

Investigation of therapeutic cancer vaccines and novel drug combinations across various cancer types.

  • Innovative treatment approaches
  • Drug resistance management
  • Survival improvement strategies

Focus on developing personalized treatment approaches based on specific genetic markers.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.